Treatment Patterns and Feasibility of Cisplatin Plus Gemcitabine in Older Patients Aged = 75 Years With Biliary Tract Cancer

Introduction Gemcitabine–cisplatin (GC) is the chemotherapy backbone of first-line therapy for locally advanced or metastatic biliary tract cancer (BTC), whether given alone or with immune checkpoint inhibitors. However, data on chemotherapy use and feasibility in patients aged ≥ 75 years remain limited. We evaluated real-world treatment patterns and the feasibility of GC in older patients with BTC. Methods We retrospectively reviewed the medical records of consecutive patients aged ≥ 75 years with pathologically confirmed BTC diagnosed at a single center between January 2013 and December 2020, before first-line immunotherapy was available. Patients with Eastern Cooperative Oncology Group performance status (PS) 0–1 and adequate organ function who received first-line palliative GC (cisplatin 25 mg/m² and gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks) were analyzed for feasibility, efficacy, and toxicity. Given the small sample size, all analyses were exploratory. Results Of the 102 patients, 54 (52.9%) received only best supportive care, while 48 (47.1%) underwent surgery or received chemotherapy or radiotherapy. In total, 28 patients (median age 80.9 years; range 75.0–90.9; 96.4% with PS 1) received palliative GC for a median of 6 cycles (range 1–13). Of these, 9 patients (32.1%) had a partial response, 11 (39.3%) had stable disease, 5 (17.9%) had progressive disease, and response was not available in 3 (10.7%) (objective response rate 32.1%, 95% confidence interval [CI] 15.9–52.4; disease-control rate 71.4%, 95% CI 51.3–86.8). Median progression-free survival was 5.3 months (95% CI 4.1–7.0; 28 events), and median overall survival was 10.5 months (95% CI 7.6–12.0; 25 deaths); the 1-year survival rate was 28.3% (95% CI 10.8–45.8). Initial dose reduction was more frequent in patients aged ≥ 80 years than in those aged < 80 years (odds ratio 15.5, 95% CI 2.1–113.4), whereas differences in progression-free and overall survival between these age groups were not statistically significant. The most common grade 3–4 toxicities were anemia (32.1%) and thrombocytopenia (21.4%); no treatment-related deaths occurred. Conclusion More than half of the patients aged ≥ 75 years with BTC in this study received best supportive care alone, reflecting both patient or caregiver preference and poor PS. In a highly selected subset of fit patients with PS 0–1 and adequate organ function, GC combination chemotherapy may be feasible and potentially effective, supported by individualized initial dose reduction and appropriate supportive care.

Authors

Publication Details

Journal
Oncology
Published
2026-11-21
DOI
https://doi.org/10.1159/ocl/aebag033
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment Patterns and Feasibility of Cisplatin Plus Gemcitabine in Older Patients Aged = 75 Years With Biliary Tract Cancer

Hee Ryeong Jang, Kyu‐Hyoung Lim, Hui-Young Lee, Su Jin Bae et al.
Oncology
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Treatment Patterns and Feasibility of Cisplatin Plus Gemcitabine in Older Patients Aged = 75 Years With Biliary Tract Cancer

Hee Ryeong Jang, Kyu‐Hyoung Lim, Hui-Young Lee, Su Jin Bae, Myoung-nam Lim, Seo-Young Song
article en

Abstract

Introduction Gemcitabine–cisplatin (GC) is the chemotherapy backbone of first-line therapy for locally advanced or metastatic biliary tract cancer (BTC), whether given alone or with immune checkpoint inhibitors. However, data on chemotherapy use and feasibility in patients aged ≥ 75 years remain limited. We evaluated real-world treatment patterns and the feasibility of GC in older patients with BTC. Methods We retrospectively reviewed the medical records of consecutive patients aged ≥ 75 years with pathologically confirmed BTC diagnosed at a single center between January 2013 and December 2020, before first-line immunotherapy was available. Patients with Eastern Cooperative Oncology Group performance status (PS) 0–1 and adequate organ function who received first-line palliative GC (cisplatin 25 mg/m² and gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks) were analyzed for feasibility, efficacy, and toxicity. Given the small sample size, all analyses were exploratory. Results Of the 102 patients, 54 (52.9%) received only best supportive care, while 48 (47.1%) underwent surgery or received chemotherapy or radiotherapy. In total, 28 patients (median age 80.9 years; range 75.0–90.9; 96.4% with PS 1) received palliative GC for a median of 6 cycles (range 1–13). Of these, 9 patients (32.1%) had a partial response, 11 (39.3%) had stable disease, 5 (17.9%) had progressive disease, and response was not available in 3 (10.7%) (objective response rate 32.1%, 95% confidence interval [CI] 15.9–52.4; disease-control rate 71.4%, 95% CI 51.3–86.8). Median progression-free survival was 5.3 months (95% CI 4.1–7.0; 28 events), and median overall survival was 10.5 months (95% CI 7.6–12.0; 25 deaths); the 1-year survival rate was 28.3% (95% CI 10.8–45.8). Initial dose reduction was more frequent in patients aged ≥ 80 years than in those aged < 80 years (odds ratio 15.5, 95% CI 2.1–113.4), whereas differences in progression-free and overall survival between these age groups were not statistically significant. The most common grade 3–4 toxicities were anemia (32.1%) and thrombocytopenia (21.4%); no treatment-related deaths occurred. Conclusion More than half of the patients aged ≥ 75 years with BTC in this study received best supportive care alone, reflecting both patient or caregiver preference and poor PS. In a highly selected subset of fit patients with PS 0–1 and adequate organ function, GC combination chemotherapy may be feasible and potentially effective, supported by individualized initial dose reduction and appropriate supportive care.

Oncology
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon